Francois Lebel News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Sirnaomics Announces Successful Completion of Cohort 1 from Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment

HONG KONG and GERMANTOWN, Md. and SUZHOU BIOBAY, China, Dec. 5, 2023 /PRNewswire/ Sirnaomics Ltd. , a leading biopharmaceutical company engaging in discovery and development of advanced RNAi.

United statesFrancois lebelSirnaomic galaheadPatrick luGroup or sirnaomicsGroup factor xi programPrnewswire sirnaomics ltdStock codeExecutive directorChief executive officerChief medical officer

Sirnaomics Announces Successful Completion Of Cohort 1 From Phase I Clinical Study Of Galnac-Based Rnai Therapeutic STP122G For Anticoagulant Treatmen

Sirnaomics Announces Successful Completion Of Cohort 1 From Phase I Clinical Study Of Galnac-Based Rnai Therapeutic STP122G For Anticoagulant Treatmen
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United statesPatrick luSirnaomic galaheadFrancois lebelPrnewswire sirnaomics ltdGroup or sirnaomicsGroup factor xi programStock codeExecutive directorChief executive officerChief medical officer

Sirnaomics Announces Successful Completion of Cohort 1 from Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment

Sirnaomics Announces Successful Completion of Cohort 1 from Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment
sina.com.hk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com.hk Daily Mail and Mail on Sunday newspapers.

Patrick luFrancois lebelSirnaomic galaheadSirnaomics ltdGroup or sirnaomicsGroup factor xi programStock codeExecutive directorChief executive officerChief medical officer

Sirnaomics Promotes Francois Lebel, M D to Chief Medical Officer

Sirnaomics Promotes Francois Lebel, M D to Chief Medical Officer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesFrancois lebelPatrick luRegulatory affairsRoyal college of physicians canadaMcgill universityResearch developmentPrnewswire sirnaomics ltdHarvard medical schoolClinical developmentDrug administrationGroup or sirnaomicsChief medicalSenior vice presidentSquamous cell carcinomaExecutive director

Sirnaomics Appoints Dr Francois Lebel as Senior Vice President for Preclinical and Clinical Development

/PRNewswire/ Sirnaomics Ltd. (the "Company", Stock Code: 2257.HK, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical.

Patrick luFrancois lebelSpectrum pharmaceuticalsSirnaomics ltdDrug administrationResearch developmentChiron corporationStock codeSenior vice presidentExecutive directorChief executive officerBaxter healthcareExecutive vice presidentChief medical officer